KPV

KPV is a naturally occurring tripeptide composed of the amino acids lysine-proline-valine (Lys-Pro-Val). It represents the C-terminal fragment (amino acids 11-13) of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino acid peptide that plays important roles in pigmentation, inflammation, and energy homeostasis. Despite being only three amino acids long, KPV retains significant anti-inflammatory activity from the parent α-MSH molecule while lacking the melanogenic (skin-darkening) effects.

The anti-inflammatory mechanism of KPV primarily involves inhibition of the NF-κB signaling pathway, a master regulator of inflammatory gene expression. Studies have shown that KPV can enter cells and directly interact with NF-κB pathway components, reducing the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. This targeted mechanism makes it an interesting research compound for inflammatory conditions without the broad immunosuppressive effects of corticosteroids.

Research on KPV has focused particularly on gastrointestinal inflammation. Studies in animal models of inflammatory bowel disease (IBD), including both ulcerative colitis and Crohn's disease models, have shown that KPV can reduce intestinal inflammation, decrease disease activity scores, and promote mucosal healing. Notably, oral administration has shown efficacy in these models, suggesting the peptide can exert local anti-inflammatory effects in the gut, which is advantageous for treating GI conditions.

Additional research has explored KPV's potential in skin inflammation, wound healing, and antimicrobial applications. The peptide has demonstrated anti-inflammatory effects in models of contact dermatitis and has shown antimicrobial activity against certain pathogens, including Staphylococcus aureus and Candida albicans. Its small size, stability, and dual anti-inflammatory/antimicrobial properties make it an attractive candidate for both topical and systemic applications, though human clinical trials are still needed.